Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Announces Positive Phase 1 Results for TERN-601 in Obesity Treatment
Summary
Terns Pharmaceuticals, Inc. announced positive top-line data from its Phase 1 trial of TERN-601, a once-daily oral GLP-1R agonist for obesity treatment. The trial demonstrated statistically significant weight loss with maximum placebo-adjusted mean weight loss of 4.9% at the highest dose. TERN-601 was well tolerated with mostly mild adverse events. The company plans to advance TERN-601 into Phase 2 clinical trials in 2025.
Profitelligence Alerts
Get alerts for TERN
Be first to know when Terns Pharmaceuticals Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic candidates targeting liver disease and oncology. Its primary function is to advance its pipeline of clinical and preclinical drug candidates that address significant unmet medical needs. One of the company's main focuses is on non-alcoholic steatohepatitis (NASH), a progressive liver disease. Through innovative approaches, Terns Pharmaceuticals explores various mechanisms to treat NASH, including small molecules designed to reduce liver inflammation and fibrosis. Beyond liver disease, the company is expanding its platform to include oncology, diversifying its impact in the healthcare industry. As a key player in the biopharmaceutical sector, Terns Pharmaceuticals Inc. contributes to the growing landscape of targeted therapies. With a dedicated emphasis on research and development, the company plays an essential role in pushing the boundaries of treatment options, potentially transforming the management of chronic liver diseases and cancer.
Official SEC Documents
Advertisement